Live data · NADAC + Part D CY24 · reviewed daily

Emtricitabine, Rilpivirine, Tenofovir Disoproxil

First FDA approval2025-05-27
Generic availableYes · 2 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$114.50/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$114.50
Across all dosage forms in distribution.
Highest NADAC
$114.50
Range is tight.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema6 entries indexed · 4 visible
What is Emtricitabine, Rilpivirine, Tenofovir Disoproxil used for?

Emtricitabine, Rilpivirine, Tenofovir Disoproxil is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Emtricitabine, Rilpivirine, Tenofovir Disoproxil?

Yes. 2 ANDAs filed at FDA, 2 generic manufacturers currently shipping.

How much does my plan pay for Emtricitabine, Rilpivirine, Tenofovir Disoproxil?

Across 329 Part D plans, Emtricitabine, Rilpivirine, Tenofovir Disoproxil averages $114.50/unit (NADAC). Lowest available: $114.50/unit. Highest in distribution: $114.50/unit.

Is Emtricitabine, Rilpivirine, Tenofovir Disoproxil on the FDA shortage list?

No. Emtricitabine, Rilpivirine, Tenofovir Disoproxil is not currently on the FDA Drug Shortage Database.

2 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (3 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.